Trial Profile

Dolutegravir Impact on Residual Replication: Dolutegravir Intensification Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms DIORR

Most Recent Events

07 Mar 2018 Primary endpoint (Level of residual HIV replication in circulating CD4+ T cells) has not been met as per the results presented at the 25th Conference on Retroviruses and Opportunistic Infections.
07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections
16 Nov 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com